Two Columbia University Medical Center faculty members were present today when President Obama provided details of the precision medicine initiative he announced during this year’s State of the Union address.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.
A CUMC study found that the use of generic aromatase inhibitors, which cost considerably less than their brand-name counterparts, increased treatment adherence by 50 percent.
Using an innovative algorithm, CUMC researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
Research from Columbia shows that nerves play a critical role in stomach cancer growth and blocking nerve signals using surgery or Botox® could provide an effective therapy for the disease.